Browsing by Author "Ahn, Myung-Ju"
Now showing items 1-6 of 6
-
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
Cho, Byoung Chul; Lee, Jong Seok; Wu, Y. L.; Çiçin, Irfan; Ahn, Myung-Ju; cobo, manuel; FELIP, ENRIQUETA (Elsevier, 2023-12) -
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Felip Font, Enriqueta (American Society of Clinical Oncology, 2020-11-01) -
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Felip Font, Enriqueta (Elsevier, 2021-12-01) -
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Ahn, Myung-Ju; Kim, Hye R.; Yang, James C. H.; Han, Ji-Yu; Li, Jacky Y.C.; Hochmair, Maximilian J.; Felip Font, Enriqueta (Elsevier, 2022-12) -
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
Ou, Sai-Hong; Nishio, Makoto; Ahn, Myung-Ju; Barlesi, Fabrice; Felip Font, Enriqueta; Mok, Tony; Zhou, Caicun (Elsevier, 2022-12) -
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design
Riely, Gregory; Ahn, Myung-Ju; Felip Font, Enriqueta; Ramalingam, Suresh; Smit, Egbert; Tsao, Anne (Future Medicine, 2022-03)